{"log_id": 5682801020701928908, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.00038, "average": 0.986809, "min": 0.953176}, "location": {"width": 92, "top": 109, "height": 25, "left": 181}, "words": "药理作用"}, {"probability": {"variance": 0.003565, "average": 0.972266, "min": 0.676627}, "location": {"width": 852, "top": 126, "height": 42, "left": 181}, "words": "唑米膦酸的药理作用主要是抑制骨吸收,其作用机制尚不完全清楚,可能与多方面作用有关"}, {"probability": {"variance": 0.003948, "average": 0.975641, "min": 0.693191}, "location": {"width": 863, "top": 159, "height": 43, "left": 179}, "words": "唑来酸在体外可抑制碱骨细胞动,诱导破骨细胞凋亡,还可通过与骨的结合阻断假骨细"}, {"probability": {"variance": 0.011391, "average": 0.957495, "min": 0.603286}, "location": {"width": 863, "top": 193, "height": 41, "left": 180}, "words": "胞对矿化骨和软骨的吸收。唑来酸还可以抑制由肿瘤释放的多种刺激因子引起的破骨细胞"}, {"probability": {"variance": 0.000306, "average": 0.989217, "min": 0.945529}, "location": {"width": 199, "top": 237, "height": 28, "left": 180}, "words": "活动增强和骨钙释放"}, {"probability": {"variance": 0.055053, "average": 0.828981, "min": 0.430374}, "location": {"width": 88, "top": 273, "height": 25, "left": 183}, "words": "理研究"}, {"probability": {"variance": 3.4e-05, "average": 0.996263, "min": 0.986148}, "location": {"width": 88, "top": 306, "height": 25, "left": 182}, "words": "遗传毒性"}, {"probability": {"variance": 0.004515, "average": 0.981945, "min": 0.597055}, "location": {"width": 861, "top": 323, "height": 47, "left": 181}, "words": "本品Ames细菌回复突变试验、中国仓鼠卵巢细胞染色体畸变试验、中国仓鼠基因突变试验"}, {"probability": {"variance": 4.5e-05, "average": 0.995503, "min": 0.979544}, "location": {"width": 286, "top": 369, "height": 32, "left": 181}, "words": "和大鼠微核试验结果均为阴性"}, {"probability": {"variance": 0.001045, "average": 0.980756, "min": 0.924757}, "location": {"width": 87, "top": 407, "height": 24, "left": 183}, "words": "生殖毒性"}, {"probability": {"variance": 0.004376, "average": 0.97631, "min": 0.570229}, "location": {"width": 864, "top": 435, "height": 44, "left": 180}, "words": "雌性大鼠从交配前15天至怀孕期结束皮下注射本品0.01、0.03或0.1mg/kg/日(AUC为人静"}, {"probability": {"variance": 0.001558, "average": 0.984172, "min": 0.794514}, "location": {"width": 863, "top": 477, "height": 43, "left": 181}, "words": "脉注射4mg时的0.07、0.2和1.2倍),高剂量纽动物出现排卵抑制和受孕率下降。中剂量和"}, {"probability": {"variance": 0.004455, "average": 0.983145, "min": 0.577649}, "location": {"width": 851, "top": 518, "height": 44, "left": 183}, "words": "高剂量组动物均出现胚胎植入前丢火增加、植入胚数及活胎数减少,新生鼠的存活率下降"}, {"probability": {"variance": 0.000893, "average": 0.987123, "min": 0.873613}, "location": {"width": 853, "top": 560, "height": 43, "left": 181}, "words": "所有剂量组母鼠均出现难产及围产期死亡率增加。母鼠死亡的原因可能与药物抑制骨钙动员"}, {"probability": {"variance": 0.002165, "average": 0.985244, "min": 0.772008}, "location": {"width": 562, "top": 609, "height": 35, "left": 185}, "words": "导致产期低血钙有关,这可能是双膦酸类药物共有的作用"}, {"probability": {"variance": 0.002563, "average": 0.982012, "min": 0.671861}, "location": {"width": 817, "top": 665, "height": 40, "left": 226}, "words": "雌性大鼠怀孕期间皮下注射本品0.1、0.2或0.mg/kg/日(AUC为人静脉注射4mg时的"}, {"probability": {"variance": 0.001766, "average": 0.982492, "min": 0.793928}, "location": {"width": 865, "top": 705, "height": 43, "left": 182}, "words": "12、2.4或4.8倍),中、高剂量组动物出现胚胎植入前或植入后丢失增加、活胎数减少、胎"}, {"probability": {"variance": 0.001727, "average": 0.982408, "min": 0.793231}, "location": {"width": 865, "top": 748, "height": 41, "left": 183}, "words": "仔骨、内脏和外观畸形。高剂量组动物胎仔的骨骼畸形表现为未骨化和骨化不全,骨骼增"}, {"probability": {"variance": 0.003522, "average": 0.97816, "min": 0.704557}, "location": {"width": 861, "top": 791, "height": 40, "left": 185}, "words": "厚、弯曲或缩短等。高剂量组还可见品状体缩小、小脑发育不全、肝小叶缩小或缺失、肺叶"}, {"probability": {"variance": 0.00482, "average": 0.981281, "min": 0.616754}, "location": {"width": 863, "top": 833, "height": 41, "left": 185}, "words": "变形、血管扩张、腭裂、水肿等毒性反应。低剂量组动物胎仔也出现骨骼畸形。本试验中高"}, {"probability": {"variance": 0.004752, "average": 0.971576, "min": 0.678755}, "location": {"width": 713, "top": 877, "height": 39, "left": 186}, "words": "剂量组母体动物出现体重和摄食量下降,提示试验已达到最高药物暴露水平"}, {"probability": {"variance": 0.009994, "average": 0.863205, "min": 0.738715}, "location": {"width": 126, "top": 882, "height": 55, "left": 933}, "words": "有限公"}, {"probability": {"variance": 0.00083, "average": 0.983198, "min": 0.902298}, "location": {"width": 256, "top": 945, "height": 27, "left": 228}, "words": "妊娠家兔皮下给予本品0.0"}, {"probability": {"variance": 0.003434, "average": 0.964382, "min": 0.769833}, "location": {"width": 520, "top": 933, "height": 41, "left": 529}, "words": "3、0.1mgkg/日(AUC小于或等于人静脉注射4mg时的"}, {"probability": {"variance": 0.014893, "average": 0.959441, "min": 0.399711}, "location": {"width": 843, "top": 976, "height": 43, "left": 185}, "words": "05倍),未观察到本品对胎仔的毒性。各用药纽动物(按相对体表面积折算,量大于或"}, {"probability": {"variance": 0.000961, "average": 0.989408, "min": 0.847952}, "location": {"width": 863, "top": 1018, "height": 43, "left": 187}, "words": "于人静脉用药剂量4mg的0.05倍)均出现母体死亡和流产,此现象可能与药物引起的低血钙"}, {"probability": {"variance": 8e-06, "average": 0.997051, "min": 0.994273}, "location": {"width": 48, "top": 1073, "height": 26, "left": 187}, "words": "有关"}, {"probability": {"variance": 8e-06, "average": 0.997763, "min": 0.993741}, "location": {"width": 72, "top": 1131, "height": 25, "left": 185}, "words": "致癌性"}, {"probability": {"variance": 0.02238, "average": 0.916206, "min": 0.383343}, "location": {"width": 818, "top": 1153, "height": 45, "left": 232}, "words": "采用小鼠和大鼠进行了常规终生致癌试验研究小鼠经给本05和20mgkg"}, {"probability": {"variance": 0.013766, "average": 0.933913, "min": 0.580636}, "location": {"width": 677, "top": 1202, "height": 42, "left": 188}, "words": "日(按相对体表面积折算,剂量大于或等于人静脉用药剂量g的0.00"}, {"probability": {"variance": 0.036837, "average": 0.874124, "min": 0.509012}, "location": {"width": 131, "top": 1203, "height": 30, "left": 919}, "words": "新所有给药组动"}, {"probability": {"variance": 0.025925, "average": 0.894074, "min": 0.494651}, "location": {"width": 865, "top": 1241, "height": 47, "left": 187}, "words": "物 Harderian(副腺)腺瘤的发生率增加。大鼠经口给子泰品0.0.5和20mg/g日(按相"}, {"probability": {"variance": 0.002093, "average": 0.981959, "min": 0.738583}, "location": {"width": 849, "top": 1284, "height": 44, "left": 186}, "words": "对体表面积折算,剂量小于或等于人静脉用药剂量4mg的02倍),未见肿瘤发生率的增加"}, {"probability": {"variance": 2e-06, "average": 0.998573, "min": 0.996712}, "location": {"width": 142, "top": 1354, "height": 26, "left": 196}, "words": "【药代动力学】"}, {"probability": {"variance": 0.000382, "average": 0.98524, "min": 0.952013}, "location": {"width": 81, "top": 1398, "height": 25, "left": 188}, "words": "1、分布"}, {"probability": {"variance": 5.4e-05, "average": 0.995548, "min": 0.96057}, "location": {"width": 819, "top": 1428, "height": 40, "left": 234}, "words": "64名癌症或骨转移患者静脉滴注单剂量或多剂量(28天4次)2、4、8或16mg,滴注时"}, {"probability": {"variance": 0.000394, "average": 0.99229, "min": 0.877446}, "location": {"width": 865, "top": 1470, "height": 41, "left": 190}, "words": "间5或15分钟,滴注后血浆中唑来膦酸浓度的降低符合三相消除过程,滴注完毕迅速从峰浓"}, {"probability": {"variance": 0.016545, "average": 0.951774, "min": 0.449908}, "location": {"width": 868, "top": 1515, "height": 38, "left": 188}, "words": "度值下降,24小时后血药浓度不到Cmax的1%。最初两相的半衰期tpa为0.24小时,t2B"}, {"probability": {"variance": 0, "average": 0.987458, "min": 0.987458}, "location": {"width": 20, "top": 1710, "height": 29, "left": 50}, "words": "/"}], "language": 3}